NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Concerto Biosciences

Concerto Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.concertobio.com/

Last Round

Series A

Nov 2, 2022

Total Funding Raised

$23.6M

Company Overview

Concerto Biosciences is a biotechnology company that develops microbe-based products by measuring and mapping microbial interactions to address needs in skin health, women's health, and food science.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

microbiomemicrobial communitiesmicrofluidicshigh-throughput screeningkChipsynthetic biologysynbiobiotech discoverymicrobial ecologykAIpredictive biologydrug discoveryagricultural biotechnologyagtechbio-foundrymicrobial engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Concerto Biosciences Comparables

Compare Concerto Biosciences with similar companies based on industry and business-model similarity.

Concerto Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pluton Biosciences
84%
Microbiotica
77%
Kanvas Biosciences
69%

Concerto Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 2, 2022
GrantSep 1, 2022
GrantJul 1, 2022

Key People

Founding team and executive leadership

Jared Kehe

Cofounder And Chief Scientific Officer

Founding Team

Cheri Ackerman

Cofounder CEO

Founding Team

Bernardo Cervantes

Chief Operating Officer

Executive Team

Concerto Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2026

    Partnered with Sacco System for development and commercialisation.

  • Jan 29, 2025

    Stewart Campbell appointed as Independent Director.

Concerto Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Concerto Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Concerto Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range25
Year Founded2020
Last FundingNov 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.